Development of BRAFV600E-positive acute myeloid leukemia in a patient on long-term dabrafenib for multisystem LCH

Blood Adv. 2022 Apr 26;6(8):2681-2684. doi: 10.1182/bloodadvances.2021006229.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Imidazoles / adverse effects
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / genetics
  • Oximes* / adverse effects

Substances

  • Imidazoles
  • Oximes
  • dabrafenib